Common questions
What does the CJC-1295 + Ipamorelin stack do?
It stimulates the body's own growth hormone release through two separate receptor pathways. CJC-1295 (no DAC) hits GHRH receptors on the pituitary, telling the pituitary to make GH. Ipamorelin hits the ghrelin receptor on the same cells, triggering the actual GH pulse. The combination is described in pharmacology literature as synergistic. Neither compound is FDA-approved for any clinical use.
What is the standard CJC-1295 + Ipamorelin dosage?
The most common research-planning range is 100-300 mcg of each peptide, injected subcutaneously once daily on an empty stomach. A typical pre-blended 20 mg vial (10 mg + 10 mg) reconstituted with 3.0 mL bacteriostatic water gives a clean 6-unit insulin draw for 200 mcg of each peptide. This is research-planning context, not a personal dosing recommendation.
Open the reconstitution calculator →Should I use CJC-1295 with or without DAC?
Without DAC for Ipamorelin pairing. The no-DAC variant has a 30-minute to 2-hour half-life that matches Ipamorelin's roughly 2-hour half-life, which preserves the body's natural pulsatile GH release. CJC-1295 with DAC has a 5.8-8.1 day half-life and produces sustained GHRH stimulation that does not pair cleanly with Ipamorelin's pulse-based mechanism.
How is the 20 mg blend reconstituted?
The featured research-planning approach is 3.0 mL of bacteriostatic water, which gives 6.67 mg/mL total concentration (3.33 mg/mL of each peptide). On a U-100 insulin syringe, 3 units delivers 100 mcg of each peptide, 6 units delivers 200 mcg, and 9 units delivers 300 mcg.
Check 20 mg in 3 mL in the calculator →How long is a typical cycle?
Most research-planning cycles run 8-12 weeks on, followed by 4 weeks off. Extended plans go 16 weeks on, 8 weeks off. Off-cycle periods are commonly described as a way to reduce the chance of receptor desensitization with sustained ghrelin-receptor stimulation. Long-term safety beyond 90 days has not been studied for the combined blend.
What are the main side effects?
Commonly reported: temporary facial flushing, mild water retention in the first 1-2 weeks, vivid dreams, deeper sleep, and a small post-injection hunger bump from Ipamorelin. Concerns that require attention: carpal tunnel-style tingling (signals excessive GH/IGF-1), elevated fasting glucose, persistent joint pain, and rare immunogenicity reactions. Anyone with active or prior cancer, pituitary disease, diabetic retinopathy, severe kidney disease, or pregnancy should not use GH-stimulating peptides.
Are CJC-1295 and Ipamorelin FDA-approved?
No. As of June 2026, neither compound is FDA-approved for any clinical use. Both were placed on FDA Category 2 in September 2023, removed in September 2024 after withdrawn nominations, and reviewed by PCAC in late 2024 with FDA recommending against 503A Bulks inclusion. Reclassification discussions in 2026 are ongoing but no formal change has been published.
Is there direct human research on the CJC-1295 + Ipamorelin blend?
No published human randomized trial has tested the CJC-1295 (no DAC) + Ipamorelin combination at the daily 200-300 mcg doses common online. The case for the stack rests on each compound's individual human pharmacokinetic data plus cellular and animal evidence that the two pathways are synergistic on the same pituitary cell.